Breast cancer who had progressed on previous patterns trastuzumabcontaining ve showed an overall response rate of 5.1%. A phase II study evaluated the safety and efficiency of lapatinib monotherapy in chemotherapy-refractory Ren tumors. This study included two cohorts LY317615 PKC inhibitor of patients, HER-2 positive and HER-2 negative. over 95% of patients had had stage IV disease and 27 OncoTargets 2008:1 and lapatinib therapy in breast cancer, almost all patients U 3 or more lines of cancer therapy again before. Ninety seven percent of patients had 2 positive again At least 12 U-w Weeks of treatment with trastuzumab before. Lapatinib 1500 mg t Was possible with dose reduction to 1250 mg in the case of toxicity t grade 3/4 managed. The best response was observed in the cohort of HER-2 positive.
There was an overall response rate Factor Xa activity of 1.4% in the cohort of HER-2 positive and 0.0% in the cohort of HER-2 negative. The independent Independent verification reports that 5.7% of the 2-positive patients again U t is a clinical benefit, but there was no CB in group 2 SA negative. The median overall survival time was 29.4 weeks versus 18.6 weeks. These responses were modest, but it was a heavily pretreated cohort. A Phase II trial of lapatinib monotherapy in the same in 67 Japanese patients with positive breast cancer refractory advanced / metastatic hereBenefit showed a lot in the subgroup of HER-2 positive. W Pets while the trend toward benefit in the two cohorts of its positive in these studies is the same as to why a response rate in the Japanese study are unclear.
A Phase II open-label, was launched two-stage study of lapatinib monotherapy in patients with breast cancer infl ammatory also in life. IBC is an aggressive form of breast cancer and is associated with a poor prognosis. Rst Patients were recruited in two cohorts of IBC HER 2-positive and EGFR-positive / negative HER-2 that had progressed on prior chemotherapy or trastuzumab. Patients were treated with lapatinib and the reaction was measured by RECIST, and skin biopsies. A response rate of 50% was observed in the first cohort of its 2-positive patients, and this cohort was to include 126 patients. There was a partial response in 15 patients in the EGFR positive / negative HER-2 cohort, and enrollment in this arm was closed. The vorl INDICATIVE analysis ridiculed Ngerte arm HER 2 shows a positive rate of approximately 40% response and the subgroup analysis of tumors shows trastuzumabrefractory, that approx Hr 50%.
These results suggest that lapatinib monotherapy in the treatment of active refractory recurrent / Rem HER 2 positive IBC. A phase II study evaluated the clinical efficacy and safety of lapatinib as a treatment fi rst line in locally advanced or metastatic HER-2 positive breast cancer without HER-2 targeted therapy. The overall response rate was 24% and not his Signifi cantly differ between the two dose groups. The median duration of response was 28.4 weeks and progression-free survival was 63% after 4 months and 43% after 6 months. This study suggests an r Fi rst line of lapatinib for locally advanced or metastatic HER-2 positive breast cancer. It was found that patients with trastuzumab HER treated 2-positive breast cancer, an hour Here Incidence of Table 3 Phase II studies of lapatinib monotherapy in advanced / metastatic breast cancer in the study population tend ID No. lapatinib dose-rate EGF20002 1250 mg, 1500 mg modified refractory T ABC /